#67 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
A post-market surveillance study examined the composition and safety profile of commercially available CBD products, assessing their quality control and potential for drug-drug interactions. The research evaluated whether marketed CBD products contained the labeled cannabidiol concentrations and identified contaminants or undisclosed compounds that could affect patient safety. The findings revealed significant variability in product composition and highlighted risks for clinically important interactions when CBD is used concurrently with medications metabolized through the cytochrome P450 system. These quality and safety concerns are particularly relevant for clinicians prescribing or recommending CBD to patients taking other medications, as unlabeled contaminants or mislabeled potencies could lead to unexpected drug interactions or adverse effects. The lack of FDA oversight of CBD products in many markets means clinicians cannot rely on standardized labeling or third-party verification for most commercial products. Physicians should counsel patients to seek independently verified CBD products, disclose all CBD use during medication reviews, and monitor for signs of drug interactions, particularly when prescribing drugs with narrow therapeutic windows.
“What this surveillance work highlights is a real gap between what’s on the label and what’s actually in these products, along with concerning variability in CBD potency and cannabinoid profiles across the market. Until we have more robust federal oversight and standardized testing requirements, clinicians need to counsel patients that ‘CBD’ from one manufacturer may be quite different from another, and we frankly don’t have enough data yet on how these unlabeled constituents interact with common medications patients are already taking.”
🔬 This surveillance study highlighting compositional variability and drug-drug interaction potential in commercial CBD products underscores a critical gap between patient use and product standardization in clinical practice. Clinicians should recognize that the unregulated nature of most CBD products means patients may be consuming inconsistent doses, unlisted cannabinoids, or contaminants that could alter metabolism of concurrent medications, particularly those metabolized through CYP3A4 and CYP2C19 pathways. While CBD’s therapeutic potential in certain conditions remains under investigation, the heterogeneity of available products and limited post-market oversight complicate evidence-based counseling. Providers caring for patients using or considering CBD should screen for drug interactions, request specific product information from patients when available, and remain aware that “CBD only” labels may not reflect actual composition. Given these uncertainties, a pragmatic approach involves documenting CBD use in medication reconciliation, counseling patients
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
